Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019